Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,798
Companies 1,771
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,798 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Recently updated

FDA-approved

Showing page 28 of 200 · By data quality, then INN

  1. nitroglycerin

    GONITRO Regeneron Ireland Designated Activity Company (DAC)

    INTRA-ANAL FDA: approved · NMPA: clinical trials

  2. nizatidine

    NIZAC Alphapharm Pty Ltd

    ORAL FDA: approved · TGA: approved

  3. norepinephrine bitartrate

    NOREPINEPHRINE BITARTRATE Amneal Pharma Europe Ltd

    INJECTION FDA: approved

  4. norethindrone

    NOR-QD Amneal Pharma Europe Ltd

    ORAL-28 FDA: approved

  5. norethindrone acetate

    NORETHINDRONE ACETATE Amneal Pharma Europe Ltd

    ORAL FDA: approved

  6. nortriptyline hydrochloride

    NORTRIPTYLINE HYDROCHLORIDE Teva Pharma GmbH

    ORAL FDA: approved

  7. nystatin

    MYCOSTATIN ORAL DROPS Lacuna Pharma Pty Ltd

    TOPICAL FDA: approved · TGA: approved

  8. obecabtagene autoleucel

    AUCATZYL Autolus GmbH

    EMA: approved

    L01XL

  9. octocog alfa

    ADVATE Takeda

    EMA: approved

    B02BD02

  10. octreotide acetate

    OCTREOTIDE ACETATE Teva Pharma GmbH

    INJECTION FDA: approved

  11. odronextamab

    ORDSPONO Regeneron UK Limited

    EMA: approved

    Not yet assigned

  12. ofloxacin

    OCUFLOX AbbVie

    OPHTHALMIC FDA: approved · TGA: approved

  13. olanzapine

    APO-OLANZAPINE ODT Alphapharm Pty Ltd

    INTRAMUSCULAR FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    N05AH03

  14. olezarsen sodium

    TRYNGOLZA (AUTOINJECTOR) IONIS PHARMACEUTICALS INC

    SUBCUTANEOUS FDA: approved

  15. olmesartan medoxomil

    BENICAR Amneal Pharma Europe Ltd

    ORAL FDA: approved

  16. olopatadine hydrochloride

    OLOPATADINE HYDROCHLORIDE Amneal Pharma Europe Ltd

    OPHTHALMIC FDA: approved

  17. olutasidenib

    REZLIDHIA RIGEL PHARMACEUTICALS INC

    ORAL FDA: approved

  18. omacetaxine mepesuccinate

    TEKINEX Teva Pharma GmbH

    SUBCUTANEOUS FDA: approved · EMA: application withdrawn

    L01XX40

  19. omega-3-acid ethyl esters

    OMEGA-3-ACID ETHYL ESTERS Amneal Pharma Europe Ltd

    ORAL FDA: approved

  20. omeprazole

    ACIMAX TABLETS Alphapharm Pty Ltd

    ORAL FDA: approved · TGA: approved

  21. ondansetron

    APX-ONDANSETRON Alphapharm Pty Ltd

    INJECTION FDA: approved · TGA: approved

  22. ondansetron hydrochloride

    ONDANSETRON HYDROCHLORIDE Amneal Pharma Europe Ltd

    INJECTION FDA: approved

  23. opicapone

    ONGENTYS Lacuna Pharma Pty Ltd

    ORAL FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    N04

  24. oseltamivir phosphate

    OSELTAMIVIR PHOSPHATE Amneal Pharma Europe Ltd

    ORAL FDA: approved

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,798 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.